VCIM
KLRS

Velan Capital Investment Management’s Kalaris Therapeutics KLRS Stock Holding History

Velan Capital Investment Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104K Buy
+18,000
New +$160K 0.07% 44

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Velan Capital Investment Management's KLRS Position: Q1 2026 in Review

Velan Capital Investment Management opened a new position in Kalaris Therapeutics (KLRS) in Q1 2026: 18,000 shares worth $104K. The stake represents 0.07% of the portfolio and ranks #44 among its holdings.

58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Velan Capital Investment Management held 18,000 shares of Kalaris Therapeutics worth $104K as of Q1 2026.
  • Kalaris Therapeutics was a new Velan Capital Investment Management position in Q1 2026.
  • Kalaris Therapeutics made up 0.07% of Velan Capital Investment Management's portfolio in Q1 2026, its #44 holding.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Velan Capital Investment Management's 13F filing for Q1 2026, filed 15 May 2026.